Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1395 • ACR Convergence 2022
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao-Fan Fang¹ and Lai-Chu See², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan
Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
Abstract Number: 2121 • ACR Convergence 2022
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Laura Pina Vegas¹, Emilie sbidian² and Pascal Claudepierre³, ¹Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ²Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³Paris Est Creteil University, Creteil, France
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…
Abstract Number: 0547 • ACR Convergence 2022
Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Nicolas Rosine¹, Surya Koturan¹, Vincent Guillemot², Claire Leloup¹, Fanni Veress¹, Tharshana Stephen¹, Hanan Yahia-Cherbal¹, Jérémie SELLAM³, Francis Berenbaum⁴, Natalia Pietrosemoli¹, Elisabetta Bianchi¹, Corinne MIceli⁵ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁴Sorbonne University - Saint-Antoine hospital, Paris, France, ⁵APHP, Paris, France
Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
George A Karpouzas¹, Zoltan Szekanecz², Eva Baecklund³, Ted Mikuls⁴, Deepak L Bhatt⁵, Harry Shi⁶, Cunshan Wang⁷, Gosford A Sawyerr⁸, Yan Chen⁶, Sujatha Menon⁷, Carol A Connell⁷, Steven R Ytterberg⁹ and Mahta Mortezavi⁸, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Pfizer, Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
Abstract Number: 0582 • ACR Convergence 2022
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
Xiaojuan Chai¹, Yayuan Fu¹, Lifeng Liu¹, Yuxi Yan¹, Quan Zhao¹, Xiaoqing Liu², Yixin Zou¹, Jing Dai¹, Feng Tang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Glucocorticoids (GCs) are widely used to treat a variety of autoimmune and inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, and asthma. The anti-inflammatory…
Abstract Number: 1425 • ACR Convergence 2022
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
Ran Jin¹, Silvia Kruppert², Florian Scholz², Marc Hammer², Greg Kricorian¹, David Collier³ and Jonathan Kay⁴, ¹Amgen, Inc., Thousand Oaks, CA, ²IQVIA, Frankfurt, Germany, ³Amgen Inc., Simi Valley, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Georg Pongratz², Luca Navarini³, Rodrigo Garcia Salinas⁴, Tianming Gao⁵, Marie-Claude Laliberté⁶, Ralph Lippe⁷ and Philip J Mease⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, ³Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, ⁴Hospital Italiano de La Plata, La Plata, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Québec, QC, Canada, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
Abstract Number: 0021 • ACR Convergence 2022
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…
Abstract Number: 0763 • ACR Convergence 2022
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Vibeke Strand¹, Shaun Bender² and Dorothy McCabe³, ¹Stanford University School of Medicine, Stanford, CA, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active…
Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Anna Dryja¹, Anna Lucia Buccarello², Isabelle Gaillard² and Joëlle Monnet², ¹MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, ²Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
Abstract Number: 2146 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Philip J Mease¹, Rodrigo Luppino Assad², Shigeyoshi Tsuji³, Pascal Richette⁴, Arathi Setty⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁵, Sandra Ciecinski⁶ and Filip Van den bosch⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, ³Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁴Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
Abstract Number: 0139 • ACR Convergence 2022
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Steven Feldman¹, Heimo stroissnig², Richard Kay³, Joanna Sobierska⁴, Roshan Dias⁴, Eric Guenzi⁵, Hendrik Otto², Halimuniyazi Haliduola², Abid Sattar⁶, Ruth Ruffieux⁴, Matjaz Steijger⁴ and Fausto Berti⁴, ¹Wake Forest School of Medicine, Winston-Salem, NC, ²Alvotech, Jülich, Germany, ³RK Statistics, Bakewell, United Kingdom, ⁴Alvotech, Zürich, Switzerland, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, London, United Kingdom
Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…
Abstract Number: 0768 • ACR Convergence 2022
Reevaluating Clinical Outcomes of Patients on Combination Biologics
Ryan Mathew¹, Alexa Meara², ChienWei Chiang³, Komal Paradakar³, Ambra Burrell³ and Gabriel Kirsch³, ¹The Ohio State University Medical Center, Skokie, IL, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Biologic treatments such as monoclonal antibodies have become first line treatment for many autoimmune diseases and now monoclonal antibodies are being used to treated…
Abstract Number: 1439 • ACR Convergence 2022
Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
Alan Smith¹, Pei-Ling Roerig¹, Jacob Cason², David Fancis², Brian Cooley², Mike Royal³, Vibeke Strand⁴, John Goldman⁵, Roel Querubin⁶ and Russell Ross², ¹4P Therapeutics, Peachtree Corners, GA, ²Sorrento Therapeutics, Atlanta, GA, ³Sorrento Therapeutics, San Diego, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Northside Hospital, Atlanta, GA, ⁶Atlanta Research Center for Rheumatology, Marietta, GA
Background/Purpose: The lymphatic system plays an integral role in the pathology of rheumatoid arthritis (RA)1 and mediates local RA flares2, yet most biologic therapies are…

« Previous Page
1
…
8
9
10
11
12
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].